Semax

Cognitive, neuroprotective

Status

On watchlist — not yet prescribable

Mechanism

Semax is a heptapeptide analogue of ACTH(4–7) developed by the Russian Academy of Sciences. It upregulates BDNF and its receptor TrkB, increases dopamine and serotonin activity, and has demonstrated neuroprotective effects in ischemic models. Unlike ACTH, it has no corticosteroid activity.

Indications

→Cognitive enhancement and memory

→Neuroprotection post-stroke (approved in Russia)

→ADHD and focus (off-label research)

→BDNF upregulation

Regulatory status

Semax is approved as a nasal spray in Russia and Ukraine for stroke and cognitive indications. In the US it has no FDA approval and is on the 503A Category 2 list. Not legally compoundable in the US at this time.

References

01Dolotov OV, et al. Semax, an analog of ACTH(4-7) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006.

02FDA 503A Category 2 — ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.